Imara to Webcast Conference Call of Third Quarter Financial Results

Rhea-AI Summary

Imara Inc. (Nasdaq: IMRA) will host a conference call and live webcast on November 5, 2020, at 8:30 a.m. ET to discuss its Q3 2020 financial results and business highlights. The company focuses on developing treatments for rare inherited genetic disorders of hemoglobin, including its lead product, IMR-687, a potential disease-modifying treatment for sickle cell disease and beta-thalassemia. Investors can access the webcast on the Imara website, and a replay will be available afterward.

Positive

• Imara is advancing IMR-687, a novel therapeutic targeting sickle cell disease and beta-thalassemia.
• The upcoming conference call aims to provide insights on the company's Q3 2020 financial performance.

Negative

• None.

BOSTON, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, today announced that the company will host a conference call and live webcast on Thursday, November 5, 2020, at 8:30 a.m. ET to discuss its third quarter 2020 financial results and recent business highlights.

A live webcast will be available under “Events and Presentations” in the Investors section of the company's website at imaratx.com. The conference call can be accessed by dialing +1 (833) 519-1307 (U.S. domestic) or (914) 800-3873 (international) and referring to conference ID 7573255. A replay of the webcast will be archived on the Imara website following the presentation.

About Imara
Imara Inc. is a clinical-stage biotechnology company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin. Imara is currently advancing IMR-687, a highly selective, potent small molecule inhibitor of PDE9 that is an oral, once-a-day, potentially disease-modifying treatment for sickle cell disease and beta-thalassemia. IMR-687 is being designed to have a multimodal mechanism of action that acts on red blood cells, white blood cells, adhesion mediators and other cell types. For more information, please visit www.imaratx.com

Media Contact:
Gina Nugent
Ten Bridge Communications
617-460-3579
gina@tenbridgecommunications.com 

Investor Contact:
Michael Gray
617-835-4061
mgray@imaratx.com

FAQ

What is the date of Imara's Q3 2020 earnings call?

Imara's Q3 2020 earnings call is scheduled for November 5, 2020.

How can I access the Imara earnings call?

The earnings call can be accessed by dialing +1 (833) 519-1307 for domestic calls or (914) 800-3873 for international, using conference ID 7573255.

What does Imara Inc. specialize in?

Imara specializes in developing therapeutics for rare inherited genetic disorders of hemoglobin.

What is IMR-687?

IMR-687 is a highly selective, potent small molecule inhibitor being developed for the treatment of sickle cell disease and beta-thalassemia.